CanSense

About

CanSense Ltd is a UK-based biotech company founded in 2018 and located at Swansea University. The company focuses on innovative diagnostic solutions for early cancer detection, particularly in women's cancers such as ovarian and endometrial cancers, as well as colorectal cancer. CanSense aims to improve survival rates through minimally invasive liquid biopsy blood tests, emphasizing patient involvement and real-world clinical applicability. The company has developed a successful test for colorectal cancer and is expanding its technology to address gynaecological cancers, where early detection is crucial. CanSense is committed to patient empowerment and healthcare professional engagement, ensuring that its tests are clinically relevant and scientifically robust. The company has received seed funding from the Innovation in Women’s Cancer Accelerator Fund to support its initiatives in transforming cancer diagnostics.